ICML 2019 | Long-term outcomes on tisagenlecleucel: 4 years in DLBCL and FL

Elise Chong

Elise Chong, MD, University of Pennsylvania, Philadelphia, PA, discusses the 4-year outcomes of the CD19-specific CAR T-cell therapy tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  
Similar topics